 Entered into an exclusive worldwide collaboration and option to license agreement on September 20, 2019 with ADT Pharmaceuticals, LLC ADT to develop novel small-molecule pan-RAS inhibitors and PDE10β-catenin inhibitors aimed at difficult-to-treat, genetically-defined cancers, underscoring Anchianos focus on developing therapies with targeted approaches. Anchiano believes that successful development of its pan-RAS-targeted therapy, with activity regardless of RAS isoform or mutation, has the potential for significant clinical impact across a variety of tumor types including lung, colorectal, pancreatic, melanoma and bladder cancer, and represents a substantial commercial opportunity. 